Trial Profile
A retrospective study evaluating safety of osimertinib plus chemotherapy in patients with EGFR-mutant non-small cell lung cancer
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 08 Jun 2019
Price :
$35
*
At a glance
- Drugs Osimertinib (Primary) ; Carboplatin; Docetaxel; Gemcitabine; Paclitaxel; Pembrolizumab; Pemetrexed; Ramucirumab; Vinorelbine
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- 04 Jun 2019 Results presented at the 55th Annual Meeting of the American Society of Clinical Oncology
- 28 Jun 2018 New trial record
- 05 Jun 2018 Results presented at the 54th Annual Meeting of the American Society of Clinical Oncology